Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Jaron Solsky

Jaron Solsky

Manager, Activation

Cancer Center Division

Collaboration(33)

Rachna Shroff
Michele Chu-Pilli
Alejandro Recio Boiles
Abhijeet Kumar
Hina Arif Tiwari

Page 1 of 7

Grants(9)

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREG) in Patients with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma
Active·2024·$0 / $625.4K·
External
oncology, clinical trial, drug combination, efficacy, patient safety
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Tre
Active·2024·$0 / $548.6K·
External
oncology, clinical trials, chemotherapy, cancer treatment, targeted therapy
A Phase 2a, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating LSTA1 when Added to Standard of Care (SOC) Versus Standard of Care Alone in Subjects with Advanced Solid Tumors
Active·2023·$0 / $825.5K·
External
oncology, clinical trials, immunotherapy, cancer treatment, drug efficacy
A Phase 1 Dose-Escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors and Lymphomas
Active·2023·$0 / $684.8K·
External
cancer treatment, drug trial, dose escalation, solid tumors, lymphomas
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers
Active·2023·$0 / $509.8K·
External
cancer, chemotherapy, clinical trial, treatment, combination therapy

Page 1 of 2